Claims
- 1. A copolymer comprising a polyoxypropylene/polyoxyethylene block copolymer having the following general formula:
- 2. The copolymer of claim 1, wherein the molecular weight of the hydrophobe is between approximately 7,000 to 20,000 Daltons.
- 3. The copolymer of claim 1, wherein the molecular weight of the hydrophobe is between approximately 10,000 to 15,000 Daltons.
- 4. The copolymer of claim 1, wherein the molecular weight of the hydrophobe is between approximately 12,000 to 14,000 Daltons.
- 5. The copolymer of claim 1, wherein the percentage of hydrophile (C2H40) is between approximately 2% and 25% by weight.
- 6. The copolymer of claim 1, wherein the copolymer is substantially free of unsaturation.
- 7. A vaccine comprising an antigen and an adjuvant, the adjuvant comprising a polyoxypropylene/polyoxyethylene block copolymer having the following general formula:
- 8. The vaccine of claim 7, wherein the weight of the hydrophobe is between 10,000 to 15,000. Daltons.
- 9. The vaccine of claim 7, wherein the weight of the hydrophobe is between 12,000 to 14,000. Daltons.
- 10. The vaccine of claim 7, wherein the percentage of hydrophile (C2H4O) is between approximately 5% and 25% by weight.
- 11. The vaccine of claim 7., wherein the copolymer is substantially free of unsaturation.
- 12. A method of modifying an immune response to an antigen in a human or animal comprising administering the antigen admixed with an adjuvant, the adjuvant comprising a polyoxypropylene/polyoxyethylene block copolymer having the following general formula:
- 13. The method of claim 12, wherein the weight of the hydrophobe is between 10,000 to 15,000. Daltons.
- 14. The method of claim 12, wherein the weight of the hydrophobe is between 12,000 to 14,000. Daltons.
- 15. The method of claim 12, wherein the percentage of hydrophile (C2H4O) is between approximately 2% and 25% by weight.
- 16. The method of claim 12, wherein the copolymer is substantially free of unsaturation.
- 17. A therapeutic composition for treating a human or animal comprising a compound capable of altering nucleic acid function admixed with a nonionic block copolymer, wherein the block copolymer has the following formula:
- 18. The composition of claim 17 wherein the wherein the molecular weight of the hydrophobe is between approximately 7,000 to 20,000 Daltons.
- 19. The composition of claim 17, wherein the molecular weight of the hydrophobe is between approximately 10,000 to 15,000 Daltons.
- 20. The composition of claim 17, wherein the molecular weight of the hydrophobe is between approximately 12,000 to 14,000 Daltons.
- 21. The composition of claim 17, wherein the percentage of hydrophile (C2H4O) is between approximately 5% and 25% by weight.
- 22. The composition of claim 17, wherein the copolymer is substantially free of unsaturation.
- 23. The composition of claim 17, wherein the compound capable of altering nucleic acid sequence function is selected from the group consisting of genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, and ribozymes.
- 24. The composition of claim 17, further comprising approximately 0.1% to approximately 5% by weight of a surfactant and approximately 0.5% to approximately 5% by volume of an low molecular weight alcohol.
- 25. The composition of claim 24, wherein the surfactant is Tween 80 and the alcohol is ethanol.
- 26. The composition of claim 24 further comprising an expression vector, wherein the compound capable of altering nucleic acid sequence function is a nucleic acid sequence contained in the expression vector, and the expression vector is capable of expressing the nucleic acid sequence.
- 27. A method of delivering a compound capable of altering nucleic acid sequence function to a human or animal comprising the step of administering to a human or animal a composition comprising a compound capable of altering nucleic acid sequence function admixed with a nonionic block copolymer, wherein the block copolymer has the following formula:
- 28. The method of claim 27, wherein the molecular weight of the hydrophobe is between approximately 7,000 to 20,000 Daltons.
- 29. The method of claim 27, wherein the molecular weight of the hydrophobe is between approximately 10,000 to 15,000 Daltons.
- 30. The method of claim 27, wherein the molecular weight of the hydrophobe is between approximately 12,000 to 14,000 Daltons.
- 31. The method of claim 27, wherein the percentage of hydrophile (C2H4O) is between approximately 2% and 25% by weight.
- 32. The method of claim 27, wherein the copolymer is substantially free of unsaturation.
- 33. The method of claim 27 wherein the compound capable of altering nucleic acid sequence function is selected from the group consisting of genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, and ribozymes.
- 34. The method of claim 33 further comprising approximately 0.1% to approximately 5% by weight of a surfactant and approximately 0.5% to approximately 5% by volume of an low molecular weight alcohol.
- 35. The method of claim 34 wherein the surfactant is Tween 80 and the alcohol is ethanol.
- 36. The method of claim 33 further comprising an expression vector, wherein the compound capable of altering nucleic acid sequence function is a nucleic acid sequence contained in the expression vector, and the expression vector is capable of expressing the nucleic acid sequence.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This patent application is a continuation-in-part of pending U.S. patent application Ser. No. 08/292,814, filed on Aug. 9, 1994.
Continuations (3)
|
Number |
Date |
Country |
Parent |
09532345 |
Mar 2000 |
US |
Child |
10115332 |
Apr 2002 |
US |
Parent |
09221339 |
Dec 1998 |
US |
Child |
09532345 |
Mar 2000 |
US |
Parent |
08513162 |
Aug 1995 |
US |
Child |
09221339 |
Dec 1998 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08292814 |
Aug 1994 |
US |
Child |
08513162 |
Aug 1995 |
US |